Article
Regulatory Policy May Not Stop Comparative Efficacy Trials
Rating:
0.0
Views:
62
Likes:
1
Library:
1
Manufacturers, not regulators, may be the holdouts when it comes to eliminating comparative clinical efficacy trials, according to experts interviewed by The Center for Biosimlars®.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value